We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$16.5B
AUM Growth
+$861M
Cap. Flow
+$217M
Cap. Flow %
1.32%
Top 10 Hldgs %
30.08%
Holding
735
New
44
Increased
335
Reduced
212
Closed
49

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$60.1M
2
QCOM icon
Qualcomm
QCOM
+$53.4M
3
NU icon
Nu Holdings
NU
+$48.5M
4
AMZN icon
Amazon
AMZN
+$46.5M
5
BMA icon
Banco Macro
BMA
+$43.2M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$40.8M
2
ADBE icon
Adobe
ADBE
+$36.1M
3
VIPS icon
Vipshop
VIPS
+$33.1M
4
SBUX icon
Starbucks
SBUX
+$31.4M
5
LOW icon
Lowe's Companies
LOW
+$29.1M

Sector Composition

Rank Sector Weight
1 Technology 33%
2 Healthcare 27.47%
3 Financials 9.69%
4 Consumer Discretionary 7.72%
5 Industrials 6.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDN icon
676
Radian Group
RDN
$5.14B
– –
-72,552
Closed -$2.43M
SAGE
677
DELISTED
Sage Therapeutics
SAGE
– –
-222,000
Closed -$4.16M
SCHL icon
678
Scholastic
SCHL
$796M
– –
-17,714
Closed -$668K
SDGR icon
679
Schrodinger
SDGR
$1.12B
– –
-177,000
Closed -$4.78M
SKT icon
680
Tanger
SKT
$4.82B
– –
-174,277
Closed -$5.15M
SONY icon
681
Sony
SONY
$123B
– –
-240,835
Closed -$4.13M
SQM icon
682
Sociedad Química y Minera de Chile
SQM
$19.6B
– –
-31,500
Closed -$1.55M
STRO icon
683
Sutro Biopharma
STRO
$379M
– –
-44,042
Closed -$2.49M
TFX icon
684
Teleflex
TFX
$5.85B
– –
-3,090
Closed -$699K
TMCI icon
685
Treace Medical Concepts
TMCI
$259M
– –
-454,945
Closed -$5.94M
U icon
686
Unity
U
$12.5B
– –
-125,638
Closed -$3.35M
VERV
687
DELISTED
Verve Therapeutics
VERV
– –
-310,000
Closed -$4.12M
WYNN icon
688
Wynn Resorts
WYNN
$10.1B
– –
-5,911
Closed -$9.08M
XRAY icon
689
Dentsply Sirona
XRAY
$2.59B
– –
-89,351
Closed -$4.63M
NARI
690
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-59,095
Closed -$2.84M
AGR
691
DELISTED
Avangrid, Inc.
AGR
– –
-13,821
Closed -$504K
ALPN
692
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-415,000
Closed -$16.5M
PXD
693
DELISTED
Pioneer Natural Resource Co.
PXD
– –
-16,986
Closed -$4.46M
24 25 26 27
28

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2024 Portfolio in Review

As of Q2 2024, Candriam SCA held 735 positions worth $16.5B, up 5.5% from $15.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Candriam SCA's Q2 2024 filing shows 44 new, 335 increased, 212 reduced and 49 closed positions. Its largest new stake was Banco Macro: 754,200 shares worth $43.2M. The largest sale was Apple, an estimated $40.8M.

By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2024 buy was Banco Macro: 754,200 shares worth $43.2M.
  • Candriam SCA added most to Eli Lilly in Q2 2024, an estimated $60.1M increase.
  • Candriam SCA's biggest Q2 2024 reduction was Apple, cutting an estimated $40.8M.
  • Candriam SCA fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $16.5M.
  • Candriam SCA's ten largest holdings make up 30% of its $16.5B portfolio in Q2 2024.
  • Candriam SCA opened 44 new positions and closed 49 in Q2 2024.
  • Candriam SCA's portfolio value rose 5.5% quarter-over-quarter to $16.5B.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.